Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee

Executive Summary

Proposed treatment for elevated intraocular pressure would be first in new rho-associated protein kinase inhibitor class.

You may also be interested in...

FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week

The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.

Aerie's Rhopressa Approved Early For Glaucoma, 2018 Launch Planned

The first of Aerie's two glaucoma candidates, Rhopressa, was approved in the US and a submission for combination product Roclatan is expected next year. Rhopressa may have muted uptake in 2018, however, since it won't launch until the second quarter and half of its market is covered by Medicare Part D.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts